Toggle navigation
Home
Search
Services
Blog
Contact
About
Cloning Target Sites for the DNA-Binding Protein PAX-6
Carulli, John P.
Oscient Pharmaceuticals Corporation, Waltham, MA, United States
Search grants from John Carulli
Search grants from Oscient Pharmaceuticals Corporation
Share this grant:
:
:
Abstract
Funding
Institution
Related projects
Comments
Recent in Grantomics:
Ohio State University
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
Peripheral Nerve Distribution and Function Within the Skeleton
Public Health Strategies for Surveillance of Harmful Algal Blooms (HABS) in Flori
Neuropharmacology of neuropathic pain and addiction
Public Health Strategies for Surveillance of Harmful Algal Blooms (HABS) in Flori
Measurement &modulation of the mutation rate in humans
Recently added grants:
Project 1: Megakaryocytes as Organizers of the Hematopoietic Environment
Project 2: Extracellular Glycosylation and Blood Cell Production
Project 3: Role of Glycosaminoglycans in Hematopoiesis
Cancer Center Support Grant
Cancer Center Administration
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
2R44NS033803-02
Application #
2037906
Study Section
Special Emphasis Panel (ZRG7-SSS-2 (22))
Program Officer
Small, Judy A
Project Start
1995-02-13
Project End
1998-08-31
Budget Start
1996-09-30
Budget End
1997-08-31
Support Year
2
Fiscal Year
1996
Total Cost
Indirect Cost
Institution
Name
Oscient Pharmaceuticals Corporation
Department
Type
DUNS #
City
Waltham
State
MA
Country
United States
Zip Code
02453
Related projects
NIH 1997
R44 NS
Cloning Target Sites for the DNA-Binding Protein PAX-6
Artinger, Michael A. / Oscient Pharmaceuticals Corporation
NIH 1996
R44 NS
Cloning Target Sites for the DNA-Binding Protein PAX-6
Carulli, John P. / Oscient Pharmaceuticals Corporation
Comments
Be the first to comment on John Carulli's grant